Zongertinib (BI01810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers
RNA-seq (gene expression) · human · 90 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 90 samples: 23 conditions, mostly with about 5 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven CancersCancer discovery · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE252799_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1062724 and SRA study SRP482636. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 90 samples.
How we read this: 23 replicated groups read from 90 sample titles; they account for 90 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8007915 PC-9_YVMA-5_BI01810631_BIDx1_10mpg_24h_in_vivo_rep1 PC-9_YVMA-5_BI01810631_…
- GSM8007916 PC-9_YVMA-5_BI01810631_BIDx1_10mpg_24h_in_vivo_rep2 PC-9_YVMA-5_BI01810631_…
- GSM8007917 PC-9_YVMA-5_BI01810631_BIDx1_10mpg_24h_in_vivo_rep3 PC-9_YVMA-5_BI01810631_…
- GSM8007918 PC-9_YVMA-5_BI01810631_BIDx1_10mpg_24h_in_vivo_rep4 PC-9_YVMA-5_BI01810631_…
- GSM8007919 PC-9_YVMA-5_BI01810631_BIDx1_10mpg_24h_in_vivo_rep5 PC-9_YVMA-5_BI01810631_…
- GSM8007920 PC-9_YVMA-5_BI01810631_BIDx1_5mpg_24h_in_vivo_rep1 PC-9_YVMA-5_BI01810631_…
- GSM8007921 PC-9_YVMA-5_BI01810631_BIDx1_5mpg_24h_in_vivo_rep2 PC-9_YVMA-5_BI01810631_…
- GSM8007922 PC-9_YVMA-5_BI01810631_BIDx1_5mpg_24h_in_vivo_rep3 PC-9_YVMA-5_BI01810631_…
- GSM8007923 PC-9_YVMA-5_BI01810631_BIDx1_5mpg_24h_in_vivo_rep4 PC-9_YVMA-5_BI01810631_…
- GSM8007924 PC-9_YVMA-5_BI01810631_BIDx1_5mpg_24h_in_vivo_rep5 PC-9_YVMA-5_BI01810631_…
- GSM8007925 PC-9_YVMA-5_BI01810631_BIDx3_10mpg_24h_in_vivo_rep1 PC-9_YVMA-5_BI01810631_…
- GSM8007926 PC-9_YVMA-5_BI01810631_BIDx3_10mpg_24h_in_vivo_rep2 PC-9_YVMA-5_BI01810631_…
- GSM8007927 PC-9_YVMA-5_BI01810631_BIDx3_10mpg_24h_in_vivo_rep3 PC-9_YVMA-5_BI01810631_…
- GSM8007928 PC-9_YVMA-5_BI01810631_BIDx3_10mpg_24h_in_vivo_rep4 PC-9_YVMA-5_BI01810631_…
- GSM8007929 PC-9_YVMA-5_BI01810631_BIDx3_10mpg_24h_in_vivo_rep5 PC-9_YVMA-5_BI01810631_…
- GSM8007930 PC-9_YVMA-5_BI01810631_BIDx3_10mpg_2h_in_vivo_rep1 PC-9_YVMA-5_BI01810631_…
- GSM8007931 PC-9_YVMA-5_BI01810631_BIDx3_10mpg_2h_in_vivo_rep2 PC-9_YVMA-5_BI01810631_…
- GSM8007932 PC-9_YVMA-5_BI01810631_BIDx3_10mpg_2h_in_vivo_rep3 PC-9_YVMA-5_BI01810631_…
- GSM8007933 PC-9_YVMA-5_BI01810631_BIDx3_10mpg_2h_in_vivo_rep4 PC-9_YVMA-5_BI01810631_…
- GSM8007934 PC-9_YVMA-5_BI01810631_BIDx3_10mpg_2h_in_vivo_rep5 PC-9_YVMA-5_BI01810631_…
- GSM8007935 PC-9_YVMA-5_BI01810631_BIDx3_10mpg_6h_in_vivo_rep1 PC-9_YVMA-5_BI01810631_…
- GSM8007936 PC-9_YVMA-5_BI01810631_BIDx3_10mpg_6h_in_vivo_rep2 PC-9_YVMA-5_BI01810631_…
- GSM8007937 PC-9_YVMA-5_BI01810631_BIDx3_10mpg_6h_in_vivo_rep3 PC-9_YVMA-5_BI01810631_…
- GSM8007938 PC-9_YVMA-5_BI01810631_BIDx3_10mpg_6h_in_vivo_rep4 PC-9_YVMA-5_BI01810631_…
- GSM8007939 PC-9_YVMA-5_BI01810631_BIDx3_10mpg_6h_in_vivo_rep5 PC-9_YVMA-5_BI01810631_…
- GSM8007940 PC-9_YVMA-5_BI01810631_QDx1_10mpg_24h_in_vivo_rep1 PC-9_YVMA-5_BI01810631_…
- GSM8007941 PC-9_YVMA-5_BI01810631_QDx1_10mpg_24h_in_vivo_rep2 PC-9_YVMA-5_BI01810631_…
- GSM8007942 PC-9_YVMA-5_BI01810631_QDx1_10mpg_24h_in_vivo_rep3 PC-9_YVMA-5_BI01810631_…
- GSM8007943 PC-9_YVMA-5_BI01810631_QDx1_10mpg_24h_in_vivo_rep4 PC-9_YVMA-5_BI01810631_…
- GSM8007944 PC-9_YVMA-5_BI01810631_QDx1_10mpg_24h_in_vivo_rep5 PC-9_YVMA-5_BI01810631_…
- GSM8007945 PC-9_YVMA-5_BI01810631_QDx1_10mpg_2h_in_vivo_rep1 PC-9_YVMA-5_BI01810631_…
- GSM8007946 PC-9_YVMA-5_BI01810631_QDx1_10mpg_2h_in_vivo_rep2 PC-9_YVMA-5_BI01810631_…
- GSM8007947 PC-9_YVMA-5_BI01810631_QDx1_10mpg_2h_in_vivo_rep3 PC-9_YVMA-5_BI01810631_…
- GSM8007948 PC-9_YVMA-5_BI01810631_QDx1_10mpg_2h_in_vivo_rep4 PC-9_YVMA-5_BI01810631_…
- GSM8007949 PC-9_YVMA-5_BI01810631_QDx1_10mpg_2h_in_vivo_rep5 PC-9_YVMA-5_BI01810631_…
- GSM8007950 PC-9_YVMA-5_BI01810631_QDx1_10mpg_6h_in_vivo_rep1 PC-9_YVMA-5_BI01810631_…
- GSM8007951 PC-9_YVMA-5_BI01810631_QDx1_10mpg_6h_in_vivo_rep2 PC-9_YVMA-5_BI01810631_…
- GSM8007952 PC-9_YVMA-5_BI01810631_QDx1_10mpg_6h_in_vivo_rep3 PC-9_YVMA-5_BI01810631_…
- GSM8007953 PC-9_YVMA-5_BI01810631_QDx1_10mpg_6h_in_vivo_rep4 PC-9_YVMA-5_BI01810631_…
- GSM8007954 PC-9_YVMA-5_BI01810631_QDx1_10mpg_6h_in_vivo_rep5 PC-9_YVMA-5_BI01810631_…
+ 50 more — browse all 90 samples with per-sample file links →
- GSE311200 Comprehensive analysis of the correlation between circulating biomarkers and tumor-immune microenvironment in advanced or recurrence non-small cell lung cancer in various treatment options, i.e., immunotherapy, EGFR TKI, and chemotherapy 41 samples shares egfr, tki
- GSE294147 Blocking the transfer of damaged mitochondria from cancer cells to RGS5+ MYL9+ CAFs reduces persistent tolerance to TKIs in EGFR-mutant lung cancer 18 samples shares egfr, tki
- GSE277007 Effects of magnolin and chloroform parts of Flos Magnoliae on gene expression in NCI-H1975 cells,and genetic changes after EGFR TKI resistance 16 samples shares egfr, tki
- GSE294175 HER2 Overexpression Drives Drug-Tolerant Persisters to First-Line Amivantamab and Lazertinib in EGFR-Mutant Non-Small Cell Lung Cancer 9 samples shares her2, egfr
- GSE314455 Mycoplasma infection drives EGFR-TKI resistance through convergent transcriptomic reprogramming in non-small cell lung cancer 8 samples shares egfr, tki
- GSE300628 HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies 60 samples shares her2, therapeutic
- GSE230328 BRD8 is a therapeutic vulnerability for overcoming resistance to dual ER/HER2 blockade therapy in HR+/HER2+ breast cancer 16 samples shares her2, therapeutic
- GSE230326 BRD8 is a therapeutic vulnerability for overcoming resistance to dual ER/HER2 blockade therapy in HR+/HER2+ breast cancer [bulkRNA-seq] 12 samples shares her2, therapeutic
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.